Voyager Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Income (Loss)

(amounts in thousands, except share and per share data)


· · Year ended ·
· · December 31,
· 2023 · 2022 · 2021
Collaboration revenue	$250,008	$40,907	$37,415
Operating expenses:
Research and development	92,172	60,764	73,787
General and administrative	35,822	30,980	37,246
Total operating expenses	127,994	91,744	111,033
Operating income (loss)	122,014	(50,837)	(73,618)
Other income, net:
Interest income (expense)	11,721	1,792	(390)
Other income	3	2,653	2,811
Total other income, net	11,724	4,445	2,421
Income (loss) before income taxes	133,738	(46,392)	(71,197)
Income tax provision	1,408	16	—
Net income (loss)	$132,330	$(46,408)	$(71,197)
Other comprehensive income (loss)
Net unrealized gain (loss) on available-for-sale-securities	171	(81)	(4)
Total other comprehensive income (loss)	171	(81)	(4)
Comprehensive income (loss)	$132,501	$(46,489)	$(71,201)

Net income (loss) per share, basic	$3.08	$(1.21)	$(1.89)
Net income (loss) per share, diluted	$2.97	$(1.21)	$(1.89)

Weighted-average common shares outstanding, basic	43,020,747	38,356,810	37,668,947
Weighted-average common shares outstanding, diluted	44,569,334	38,356,810	37,668,947

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.